[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Köstler et al., 2015 - Google Patents

Targeting receptor tyrosine kinases in cancer

Köstler et al., 2015

Document ID
964787293653727791
Author
Köstler W
Zielinski C
Publication year
Publication venue
Receptor tyrosine kinases: Structure, functions and role in human disease

External Links

Snippet

Aberrations in the orderly function of the protein families of receptor tyrosine kinases (RTK) rank among the most frequent oncogenic insults in virtually any type of cancer. The present chapter delineates how RTKs are perturbed in human cancers by multiple mechanisms …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Köstler et al. Targeting receptor tyrosine kinases in cancer
Lee et al. Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis
Segovia-Mendoza et al. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence
Fiszman et al. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer
Sierra et al. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Rexer et al. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications
Shin et al. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung
US20230366035A1 (en) Biomarker for her2-positive cancer and anti-her2 therapy and applications thereof
Chen et al. Emerging molecular classifications and therapeutic implications for gastric cancer
Herrera‐Juárez et al. Targeted therapy for lung cancer: Beyond EGFR and ALK
Gu et al. Therapeutic siRNA for drug-resistant HER2-positive breast cancer
Egloff et al. Improving response rates to EGFR‐targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors
Koach et al. Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface
Saletti et al. EGFR signaling in colorectal cancer: a clinical perspective
KR102338510B1 (en) Companion diagnostic biomarker for anti-her2 therapy and use thereof
Shojaei et al. Target points in trastuzumab resistance
Hill et al. Targeted therapies in non-small-cell lung cancer
Kalamatianos et al. Anaplastic lymphoma kinase in glioblastoma: detection/diagnostic methods and therapeutic options
Han et al. The impact of systemic precision medicine and immunotherapy treatments on brain metastases
Ha et al. The tyrosine kinome dictates breast cancer heterogeneity and therapeutic responsiveness
J Oliveira-Silva et al. Anti-EGFR therapy: Strategies in head and neck squamous cell carcinoma
Orive‐Ramos et al. Regulation of the prometastatic neuregulin–MMP 13 axis by SRC family kinases: therapeutic implications
JP6858563B2 (en) Prediction of EGFR inhibitor effect by BRAF mutation detection
Rysman et al. Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas
Ye et al. Therapeutic targeting of EGFR in malignant gliomas